ProMIS Neurosciences Inc
promisneurosciences.comWhat Do They Do?
Develops antibody therapies aimed at toxic misfolded proteins for people with Alzheimer’s disease, ALS and other neurodegenerative diseases.
10-K for FY2025, filed Mar 25, 2026ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic…View ↗
We are applying our patented technology platform to build a portfolio of antibody therapies and therapeutic vaccines in neurodegenerative…View ↗
We are developing a pipeline of antibodies aimed at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative…View ↗
Who Are Their Customers?
Plans to work with pharmaceutical companies through strategic alliances or licenses; some partners may fund product development and commercialize products under a license.
Who Do They Compete With?
Competes with Alzheon, Alzinova, Cognition Therapeutics, Eisai, Eli Lilly, Novartis, Acumen Pharmaceuticals, Prothena Biosciences, Roche Holding, Wren Therapeutics, AbbVie, AC Immune, Alector, Anavex Life Sciences, Annovis Bio, Athira Pharma, Biohaven Pharmaceuticals, Denali Therapeutics, Johnson & Johnson, and Takeda Pharmaceutical
10-K for FY2025, filed Mar 25, 2026Other companies known to be developing therapies with Aβ/amyloid plaque-related targets include Alzheon, Inc., Alzinova AB, Chugai…View ↗
Loading...
